Capricor Therapeutics shareholders elect all seven director nominees and approve all proposals at 2023 Annual Meeting

CAPRICOR THERAPEUTICS, INC.

Seven director nominees elected: Litvack, Marbán, Musket, Dunbar, Manzo, Collier, Es Sabar (FOR votes 4.9M-5.9M; ~9.4M broker non-votes).
Rose, Snyder & Jacobs LLP ratified as auditor for FY2023: 14.6M FOR, 0.4M AGAINST, 1.3M abstain.
Non-binding advisory vote on named executive officer compensation approved: 4.3M FOR, 2.4M AGAINST, 0.2M abstain.
Amendment to Certificate of Incorporation for officer exculpation approved: 5.0M FOR, 1.8M AGAINST, 0.1M abstain.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CAPRICOR THERAPEUTICS, INC. shareholders approved Non-binding advisory vote on named executive officer compensation at the 2023-06-12 meeting.

Proposal: say on pay
Outcome: passed
Meeting: 2023-06-12

Exact text from the filing

FOR AGAINST ABSTAIN BROKER NON-VOTES 4,328,964 2,446,891 181,541 9,390,463

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CAPRICOR THERAPEUTICS, INC. shareholders approved Election of seven nominees to the Board of Directors to serve until the 2024 annual meeting at the 2023-06-12 meeting.

Proposal: director election
Outcome: passed
Meeting: 2023-06-12

Exact text from the filing

FOR WITHHELD BROKER NON-VOTES Frank Litvack, M.D. 5,848,468 1,108,927 9,390,464 Linda Marbán, Ph.D. 5,897,612 1,059,784 9,390,463 David B. Musket 4,907,731 2,049,664 9,390,464 George W. Dunbar, Jr. 5,838,850 1,118,545 9,390,464 Louis Manzo 5,887,307 1,070,088 9,390,464 Earl M. (Duke) Collier, Jr. 5,439,575 1,517,820 9,390,464 Karimah Es Sabar 5,899,808 1,057,588 9,390,463

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CAPRICOR THERAPEUTICS, INC. shareholders approved Approval of an amendment to the Certificate of Incorporation regarding officer exculpation at the 2023-06-12 meeting.

Proposal: charter amendment
Outcome: passed
Meeting: 2023-06-12

Exact text from the filing

FOR AGAINST ABSTAIN BROKER NON-VOTES 5,037,656 1,816,404 103,335 9,390,464

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

CAPRICOR THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Rose, Snyder & Jacobs LLP as independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-12 meeting.

Proposal: auditor ratification
Outcome: passed
Meeting: 2023-06-12

Exact text from the filing

FOR AGAINST ABSTAIN BROKER NON-VOTES 14,556,113 448,170 1,343,576 0

View on SEC.gov

1184 shareholder votes filed in the last 30 days. Browse all shareholder votes →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001558370-23-011046

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.